Growth hormone-secreting pituitary adenomas: From molecular basis to treatment options in acromegaly

Cancer Biology and Therapy

Volumn 9, Issue 7, 2010, Pages 483-492

  Sabino, Simone Magnavita ^a   Miranda, Paulo Augusto Carvalho ^a   Ribeiro Oliveira Jr , Antônio ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Acromegaly; AIP; Aryl hydrocarbon receptor interacting protein; Multiple endocrine neoplasia; Pituitary tumors; Tumorigenesis

Indexed keywords

BIM 23A387; BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; EVEROLIMUS; GROWTH HORMONE; GROWTH HORMONE RECEPTOR BLOCKING AGENT; RECEPTOR BLOCKING AGENT; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ACROMEGALY; BODY GROWTH; CARNEY COMPLEX; GROWTH HORMONE SECRETING ADENOMA; HUMAN; MORBIDITY; MULTIPLE ENDOCRINE NEOPLASIA; REVIEW;

EID: 77953690583     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.9.7.11581     Document Type: Review

References (114)

1. Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML, et al. The prevalence of pituitary adenomas: a systematic review. Cancer 2004; 101:613-9.
2. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 2006; 91:4769-75. (Pubitemid 44917305)
3. Rindi G, Villanacci V, Ubiali A. Biological and molecular aspects of gastroenteropancreatic neuroendocrine tumors. Digestion 2000; 62:19-26. (Pubitemid 30665935)
4. Levy A. Molecular and trophic mechanisms of tumorigenesis. Endocrinol Metab Clin North Am 2008; 37:23-50.
5. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971; 68:820-3.
6. Bronstein MD, Melmed S. Pituitary tumorigenesis. Arq Bras Endocrinol Metabol 2005; 49:615-25.
7. Frohman LA, Eguchi K. Familial acromegaly. Growth Horm IGF Res 2004; 14:90-6.
8. Pannett AA, Thakker RV. Somatic mutations in MEN type 1 tumors, consistent with the Knudson "two-hit" hypothesis. J Clin Endocrinol Metab 2001; 86:4371-4.
9. Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci USA 2006; 103:15558-63.
10. Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A, et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 2006; 312:1228-30. (Pubitemid 43801151)
11. Marx SJ, Agarwal SK, Kester MB, Heppner C, Kim YS, Skarulis MC, et al. Multiple endocrine neoplasia type 1: clinical and genetic features of the hereditary endocrine neoplasias. Recent Prog Horm Res 1999; 54:397-438. (Pubitemid 30074700)
12. Horvath A, Stratakis CA. Clinical and molecular genetics of acromegaly: MEN1, Carney complex, McCune-Albright syndrome, familial acromegaly and genetic defects in sporadic tumors. Rev Endocr Metab Disord 2008; 9:1-11.
13. Verges B, Boureille F, Goudet P, Murat A, Beckers A, Sassolas G, et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab 2002; 87:457-65. (Pubitemid 34158204)
14. Levy A, Lightman S. Molecular defects in the pathogenesis of pituitary tumours. Front Neuroendocrinol 2003; 24:94-127. (Pubitemid 36581937)
15. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86:5658-71. (Pubitemid 33152604)
16. Dreijerink KM, van Beek AP, Lentjes EG, Post JG, van der Luijt RB, Canninga-van Dijk MR, et al. Acromegaly in a multiple endocrine neoplasia type 1 (MEN1) family with low penetrance of the disease. Eur J Endocrinol 2005; 153:741-6.
17. Aaltonen LA. Aryl hydrocarbon receptor-interacting protein and acromegaly. Horm Res 2007; 68:127-31.
18. Igreja S, Chahal HS, Akker SA, Gueorguiev M, Popovic V, Damjanovic S, et al. Assessment of p27 (cyclin-dependent kinase inhibitor 1B) and aryl hydrocarbon receptor-interacting protein (AIP) genes in multiple endocrine neoplasia (MEN1) syndrome patients without any detectable MEN1 gene mutations. Clin Endocrinol (Oxf) 2009; 70:259-64.
19. Hayward BE, Barlier A, Korbonits M, Grossman AB, Jacquet P, Enjalbert A, et al. Imprinting of the G(s) alpha gene GNAS1 in the pathogenesis of acromegaly. J Clin Invest 2001; 107:31-6. (Pubitemid 32225362)
20. Vallar L, Spada A, Giannattasio G. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature 1987; 330:566-8.
21. Lyons J, Landis CA, Harsh G, Vallar L, Grunewald K, Feichtinger H, et al. Two G protein oncogenes in human endocrine tumors. Science 1990; 249:655-9.
22. Landis CA, Harsh G, Lyons J, Davis RL, McCormick F, Bourne HR. Clinical characteristics of acromegalic patients whose pituitary tumors contain mutant Gs protein. J Clin Endocrinol Metab 1990; 71:1416-20.
23. Johnson MC, Codner E, Eggers M, Mosso L, Rodriguez JA, Cassorla F. Gps mutations in Chilean patients harboring growth hormone-secreting pituitary tumors. J Pediatr Endocrinol Metab 1999; 12:381-7.
24. Barlier A, Gunz G, Zamora AJ, Morange-Ramos I, Figarella-Branger D, Dufour H, et al. Pronostic and therapeutic consequences of Gsalpha mutations in somatotroph adenomas. J Clin Endocrinol Metab 1998; 83:1604-10.
25. Spada A, Arosio M, Bochicchio D, Bazzoni N, Vallar L, Bassetti M, et al. Clinical, biochemical and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase. J Clin Endocrinol Metab 1990; 71:1421-6.
26. Adams EF, Brockmeier S, Friedmann E, Roth M, Buchfelder M, Fahlbusch R. Clinical and biochemical characteristics of acromegalic patients harboring gsp-positive and gsp-negative pituitary tumors. Neurosurgery 1993; 33:198-203.
27. Buchfelder M, Fahlbusch R, Merz T, Symowski H, Adams EF. Clinical correlates in acromegalic patients with pituitary tumors expressing GSP oncogenes. Pituitary 1999; 1:181-5.
28. Kim HJ, Kim MS, Park YJ, Kim SW, Park DJ, Park KS, et al. Prevalence of Gsalpha mutations in Korean patients with pituitary adenomas. J Endocrinol 2001; 168:221-6.
29. Mendoza V, Sosa E, Espinosa-de-Los-Monteros AL, Salcedo M, Guinto G, Cheng S, et al. GSPalpha mutations in Mexican patients with acromegaly: potential impact on long term prognosis. Growth Horm IGF Res 2005; 15:28-32.
30. Taboada GF, Tabet AL, Naves LA, de Carvalho DP, Gadelha MR. Prevalence of gsp oncogene in somatotropinomas and clinically non-functioning pituitary adenomas: our experience. Pituitary 2009; 12:165-9.
31. Yang I, Park S, Ryu M, Woo J, Kim S, Kim J, et al. Characteristics of gsp-positive growth hormone-secreting pituitary tumors in Korean acromegalic patients. Eur J Endocrinol 1996; 134:720-6.
32. Yasufuku-Takano J, Takano K, Morita K, Takakura K, Teramoto A, Fujita T. Does the prevalence of gsp mutations in GH-secreting pituitary adenomas differ geographically or racially? Prevalence of gsp mutations in Japanese patients revisited. Clin Endocrinol 2006; 64:91-6.
33. Ezzat S, Kontogeorgos G, Redelmeier DA, Horvath E, Harris AG, Kovacs K. In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide. Eur J Endocrinol 1995; 133:686-90.
34. Freda PU, Chung WK, Matsuoka N, Walsh JE, Kanibir MN, Kleinman G, et al. Analysis of GNAS mutations in 60 growth hormone secreting pituitary tumors: correlation with clinical and pathological characteristics and surgical outcome based on highly sensitive GH and IGF-I criteria for remission. Pituitary 2007; 10:275-82.
35. Vazquez-Martinez R, Martinez-Fuentes AJ, Pulido MR, Jimenez-Reina L, Quintero A, Leal-Cerro A, et al. Rab18 is reduced in pituitary tumors causing acromegaly and its overexpression reverts growth hormone hypersecretion. J Clin Endocrinol Metab 2008; 93:2269-76.
36. Stergiopoulos SG, bu-Asab MS, Tsokos M, Stratakis CA. Pituitary pathology in Carney complex patients. Pituitary 2004; 7:73-82.
37. Bertherat J, Horvath A, Groussin L, Grabar S, Boikos S, Cazabat L, et al. Mutations in regulatory subunit type 1A of cyclic adenosine 5′-monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes. J Clin Endocrinol Metab 2009; 94:2085-91.
38. Daly AF, Jaffrain-Rea ML, Ciccarelli A, Valdes-Socin H, Rohmer V, Tamburrano G, et al. Clinical characterization of familial isolated pituitary adenomas. J Clin Endocrinol Metab 2006; 91:3316-23.
39. Verloes A, Stevenaert A, Teh BT, Petrossians P, Beckers A. Familial acromegaly: case report and review of the literature. Pituitary 1999; 1:273-7.
40. Toledo RA, Lourenco DM Jr, Liberman B, Cunha-Neto MB, Cavalcanti MG, Moyses CB, et al. Germline mutation in the aryl hydrocarbon receptor interacting protein gene in familial somatotropinoma. J Clin Endocrinol Metab 2007; 92:1934-7.
41. Carver LA, Bradfield CA. Ligand-dependent interaction of the aryl hydrocarbon receptor with a novel immunophilin homolog in vivo. J Biol Chem 1997; 272:11452-6.
42. Meyer BK, Perdew GH. Characterization of the AhR-hsp90-XAP2 core complex and the role of the immunophilin-related protein XAP2 in AhR stabilization. Biochemistry 1999; 38:8907-17.
43. Marlowe JL, Puga A. Aryl hydrocarbon receptor, cell cycle regulation, toxicity and tumorigenesis. J Cell Biochem 2005; 96:1174-84.
44. Pollenz RS, Dougherty EJ. Redefining the role of the endogenous XAP2 and C-terminal hsp70-interacting protein on the endogenous Ah receptors expressed in mouse and rat cell lines. J Biol Chem 2005; 280:33346-56.
45. Yamada S, Yoshimoto K, Sano T, Takada K, Itakura M, Usui M, et al. Inactivation of the tumor suppressor gene on 11q13 in brothers with familial acrogigantism without multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 1997; 82:239-42.
46. Stock JL, Warth MR, Teh BT, Coderre JA, Overdorf JH, Baumann G, et al. A kindred with a variant of multiple endocrine neoplasia type 1 demonstrating frequent expression of pituitary tumors but not linked to the multiple endocrine neoplasia type 1 locus at chromosome region 11q13. J Clin Endocrinol Metab 1997; 82:486-92.
47. Gadelha MR, Une KN, Rohde K, Vaisman M, Kineman RD, Frohman LA. Isolated familial somatotropinomas: establishment of linkage to chromosome 11q13.1-11q13.3 and evidence for a potential second locus at chromosome 2p16-2. J Clin Endocrinol Metab 2000; 85:707-14.
48. Luccio-Camelo DC, Une KN, Ferreira RE, Khoo SK, Nickolov R, Bronstein MD, et al. A meiotic recombination in a new isolated familial somatotropinoma kindred. Eur J Endocrinol 2004; 150:643-8.
49. Soares BS, Eguchi K, Frohman LA. Tumor deletion mapping on chromosome 11q13 in eight families with isolated familial somatotropinoma and in 15 sporadic somatotropinomas. J Clin Endocrinol Metab 2005; 90:6580-7.
50. Yu R, Bonert V, Saporta I, Raffel LJ, Melmed S. Aryl hydrocarbon receptor interacting protein variants in sporadic pituitary adenomas. J Clin Endocrinol Metab 2006; 91:5126-9.
51. Cazabat L, Libe R, Perlemoine K, Rene-Corail F, Burnichon N, Gimenez-Roqueplo AP, et al. Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas. Eur J Endocrinol 2007; 157:1-8.
52. Naves LA, Daly AF, Vanbellinghen JF, Casulari LA, Spilioti C, Magalhaes AV, et al. Variable pathological and clinical features of a large Brazilian family harboring a mutation in the aryl hydrocarbon receptor-interacting protein gene. Eur J Endocrinol 2007; 157:383-91.
53. Iwata T, Yamada S, Mizusawa N, Golam HM, Sano T, Yoshimoto K. The aryl hydrocarbon receptor-interacting protein gene is rarely mutated in sporadic GH-secreting adenomas. Clin Endocrinol 2007; 66:499-502.
54. Georgitsi M, De ME, Cannavo S, Makinen MJ, Tuppurainen K, Pauletto P, et al. Aryl hydrocarbon receptor interacting protein (AIP) gene mutation analysis in children and adolescents with sporadic pituitary adenomas. Clin Endocrinol 2008; 69:621-7.
55. Leontiou CA, Gueorguiev M, van der SJ, Quinton R, Lolli F, Hassan S, et al. The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab 2008; 93:2390-401.
56. Cazabat L, Guillaud-Bataille M, Bertherat J, Raffin-Sanson ML. Mutations of the gene for the aryl hydrocarbon receptor-interacting protein in pituitary adenomas. Horm Res 2009; 71:132-41.
57. Yu R, Melmed S. Pituitary tumor transforming gene: an update. Front Horm Res 2004; 32:175-85.
58. Zou H, McGarry TJ, Bernal T, Kirschner MW. Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 1999; 285:418-22.
59. McCabe CJ, Boelaert K, Tannahill LA, Heaney AP, Stratford AL, Khaira JS, et al. Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab 2002; 87:4238-44.
60. Donangelo I, Marcos HP, Araujo PB, Marcondes J, Filho PN, Gadelha M, et al. Expression of retinoblastoma protein in human growth hormone-secreting pituitary adenomas. Endocr Pathol 2005; 16:53-62.
61. Simpson DJ, Hibberts NA, McNicol AM, Clayton RN, Farrell WE. Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island. Cancer Res 2000; 60:1211-6.
62. LeRiche VK, Asa SL, Ezzat S. Epidermal growth factor and its receptor (EGF-R) in human pituitary adenomas: EGF-R correlates with tumor aggressiveness. J Clin Endocrinol Metab 1996; 81:656-62.
63. Ribeiro-Oliveira A Jr, Franchi G, Kola B, Dalino P, Pinheiro SV, Salahuddin N, et al. Protein western array analysis in human pituitary tumours: insights and limitations. Endocr Relat Cancer 2008; 15:1099-114.
64. Ben-Shlomo A, Melmed S. Acromegaly. Endocrinol Metab Clin North Am 2008; 37:101-22.
65. Patel YC, Murthy KK, Escher EE, Banville D, Spiess J, Srikant CB. Mechanism of action of somatostatin: an overview of receptor function and studies of the molecular characterization and purification of somatostatin receptor proteins. Metabolism 1990; 39:63-9.
66. Lahlou H, Guillermet J, Hortala M, Vernejoul F, Pyronnet S, Bousquet C, et al. Molecular signaling of somatostatin receptors. Ann N Y Acad Sci 2004; 1014:121-31.
67. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999; 20:157-98.
68. Colao A, Pivonello R, Auriemma RS, Briganti F, Galdiero M, Tortora F, et al. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab 2006; 91:2112-8. (Pubitemid 43854991)
69. Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S, et al. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 2006; 91:1397-403.
70. Maiza JC, Vezzosi D, Matta M, Donadille F, Loubes-Lacroix F, Cournot M, et al. Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin Endocrinol 2007; 67:282-9. (Pubitemid 47076308)
71. Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, et al. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 2005; 90:4405-10. (Pubitemid 41058228)
72. Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ, et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol 2007; 66:859-68. (Pubitemid 47024274)
73. Carlsen SM, Lund-Johansen M, Schreiner T, Aanderud S, Johannesen O, Svartberg J, et al. Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab 2008; 93:2984-90.
74. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 2009; 94:1509-17.
75. Bevan JS. Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 2005; 90:1856-63.
76. Kvols L, Glusman JE, Hahn EA, Wang E, Öberg K, Anthony L, et al. The effects of pasireotide (SOM230) on health-related quality of life in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings 2007; 25:4558.
77. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002; 146:707-16. (Pubitemid 34552506)
78. Lamberts SW, van der Lely AJ, Hofland LJ. New somatostatin analogs: will they fulfil old promises? Eur J Endocrinol 2002; 146:701-5.
79. Weckbecker G, Briner U, Lewis I, Bruns C. SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates and dogs. Endocrinology 2002; 143:4123-30. (Pubitemid 35244391)
80. Shimon I. Somatostatin receptors in pituitary and development of somatostatin receptor subtype-selective analogs. Endocrine 2003; 20:265-9. (Pubitemid 36571028)
81. Thompson JS. Epidermal growth factor inhibits somatostatin-induced apoptosis. J Surg Res 1999; 81:95-100. (Pubitemid 29393785)
82. Liu D, Martino G, Thangaraju M, Sharma M, Halwani F, Shen SH, et al. Caspase-8-mediated intracellular acidification precedes mitochondrial dysfunction in somatostatin-induced apoptosis. J Biol Chem 2000; 275:9244-50. (Pubitemid 30185143)
83. Furukawa M, Raffeld M, Mateo C, Sakamoto A, Moody TW, Ito T, et al. Increased expression of insulin-like growth factor I and/or its receptor in gastrinomas is associated with low curability, increased growth and development of metastases. Clin Cancer Res 2005; 11:3233-42. (Pubitemid 40627870)
84. Thodou E, Kontogeorgos G, Theodossiou D, Pateraki M. Mapping of somatostatin receptor types in GH or/and PRL producing pituitary adenomas. J Clin Pathol 2006; 59:274-9. (Pubitemid 43344889)
85. Saveanu A, Gunz G, Dufour H, Caron P, Fina F, Ouafik L, et al. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab 2001; 86:140-5. (Pubitemid 32109787)
86. Zatelli MC, Piccin D, Tagliati F, Ambrosio MR, Margutti A, Padovani R, et al. Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH and PRL secretion. J Clin Endocrinol Metab 2003; 88:2797-802. (Pubitemid 36724458)
87. Zatelli MC, Piccin D, Bottoni A, Ambrosio MR, Margutti A, Padovani R, et al. Evidence for differential effects of selective somatostatin receptor subtype agonists on alpha-subunit and chromogranin a secretion and on cell viability in human nonfunctioning pituitary adenomas in vitro. J Clin Endocrinol Metab 2004; 89:5181-8. (Pubitemid 39391467)
88. Duran-Prado M, Malagon MM, Gracia-Navarro F, Castano JP. Dimerization of G protein-coupled receptors: new avenues for somatostatin receptor signalling, control and functioning. Mol Cell Endocrinol 2008; 286:63-8.
89. Filopanti M, Ballare E, Lania AG, Bondioni S, Verga U, Locatelli M, et al. Loss of heterozygosity at the SS receptor type 5 locus in human GH- and TSH-secreting pituitary adenomas. J Endocrinol Invest 2004; 27:937-42. (Pubitemid 40124189)
90. Lania A, Mantovani G, Spada A. Genetic abnormalities of somatostatin receptors in pituitary tumors. Mol Cell Endocrinol 2008; 286:180-6. (Pubitemid 351680235)
91. Filopanti M, Ronchi C, Ballare E, Bondioni S, Lania AG, Losa M, et al. Analysis of somatostatin receptors 2 and 5 polymorphisms in patients with acromegaly. J Clin Endocrinol Metab 2005; 90:4824-8. (Pubitemid 41159378)
92. Taboada GF, Luque RM, Neto LV, Machado EO, Sbaffi BC, Domingues RC, et al. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. Eur J Endocrinol 2008; 158:295-303.
93. Fougner SL, Borota OC, Berg JP, Hald JK, Ramm-Pettersen J, Bollerslev J. The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma. Clin Endocrinol 2008; 68:458-65. (Pubitemid 351257867)
94. Arnold R, Müller H, Schade-Brittinger C, Rinke A, Klose K, Barth P, et al. Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncolo, 27:4508.
95. Curran MP, Perry CM. Cabergoline: a review of its use in the treatment of Parkinson's disease. Drugs 2004; 64:2125-41.
96. Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De CF, Boutin JA, et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor. J Pharmacol Exp Ther 2002; 303:805-14.
97. An JJ, Cho SR, Jeong DW, Park KW, Ahn YS, Baik JH. Anti-proliferative effects and cell death mediated by two isoforms of dopamine D2 receptors in pituitary tumor cells. Mol Cell Endocrinol 2003; 206:49-62.
98. Choi EY, Jeong D, Park KW, Baik JH. G protein-mediated mitogen-activated protein kinase activation by two dopamine D2 receptors. Biochem Biophys Res Commun 1999; 256:33-40. (Pubitemid 29298912)
99. Kanasaki H, Fukunaga K, Takahashi K, Miyazaki K, Miyamoto E. Involvement of p38 mitogen-activated protein kinase activation in bromocriptine-induced apoptosis in rat pituitary GH3 cells. Biol Reprod 2000; 62:1486-94. (Pubitemid 30333728)
100. Senogles SE. D2s dopamine receptor mediates phospholipase D and antiproliferation. Mol Cell Endocrinol 2003; 209:61-9.
101. Ribeiro-Oliveira A Jr, Korbonits M, Grossman AB. The potential role of D(2) dopamine receptors as a target in the management of neuroendocrine tumors. Cancer Biol Ther 2008; 7:1979-81.
102. Zatelli MC, Piccin D, Tagliati F, Bottoni A, Ambrosio MR, Margutti A, et al. Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro. J Mol Endocrinol 2005; 35:333-41. (Pubitemid 41556180)
103. Grossrubatscher E, Veronese S, Ciaramella PD, Pugliese R, Boniardi M, De CL, et al. High expression of dopamine receptor subtype 2 in a large series of neuroendocrine tumors. Cancer Biol Ther 2008; 7:1970-8.
104. Neto LV, Machado EO, Luque RM, Taboada GF, Marcondes JB, Chimelli LM, et al. Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly. J Clin Endocrinol Metab 2009; 94:1931-7.
105. Birzniece V, Sata A, Ho KK. Growth hormone receptor modulators. Rev Endocr Metab Disord 2009; 10:145-56.
106. Kopchick JJ. Discovery and development of a new class of drugs: GH antagonists. J Endocrinol Invest 2003; 26:16-26.
107. Bianchi A, Mazziotti G, Tilaro L, Cimino V, Veltri F, Gaetani E, et al. Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly. Pituitary 2009; 12:196-9.
108. Ferone D, Pivonello R, Resmini E, Boschetti M, Rebora A, Albertelli M, et al. Preclinical and clinical experiences with the role of dopamine receptors in the treatment of pituitary adenomas. Eur J Endocrinol 2007; 156:37-43. (Pubitemid 46797842)
109. Ferone D, Saveanu A, Culler MD, Arvigo M, Rebora A, Gatto F, et al. Novel chimeric somatostatin analogs: facts and perspectives. Eur J Endocrinol 2007; 156:23-8. (Pubitemid 46797840)
110. Saveanu A, Jaquet P. Somatostatin-dopamine ligands in the treatment of pituitary adenomas. Rev Endocr Metab Disord 2009; 10:83-90.
111. Saveanu A, Gunz G, Guillen S, Dufour H, Culler MD, Jaquet P. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas. Neuroendocrinology 2006; 83:258-63. (Pubitemid 44578880)
112. Grozinsky-Glasberg S, Franchi G, Teng M, Leontiou CA, Ribeiro de OA Jr, Dalino P, et al. Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line. Neuroendocrinology 2008; 87:168-81. (Pubitemid 351563811)
113. Gorshtein A, Rubinfeld H, Kendler E, Theodoropoulou M, Cerovac V, Stalla GK, et al. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro. Endocr Relat Cancer 2009; 16:1017-27.
114. Scheithauer BW, Gaffey TA, Lloyd RV, Sebo TJ, Kovacs KT, Horvath E, et al. Pathobiology of pituitary adenomas and carcinomas. Neurosurgery 2006; 59:341-53.